Login to Your Account



Mighty Rituxan Rules NHL Roost As Amgen Weighs New Treatment

By Randall Osborne


Monday, November 17, 2003
If the drug doesn't work as a monotherapy, then give up and try to find someone else who wants to take over development. Such was the eminently practical approach taken last week by Amgen Inc. with regard to epratuzumab, also known as LymphoCide, for non-Hodgkin's lymphoma partnered with Immunomedics Inc. in North America and Australia. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription